This brand name is authorized in Nigeria
The drug SPARFON contains one active pharmaceutical ingredient (API):
|
1
Sparfloxacin
UNII Q90AGA787L - SPARFLOXACIN
|
|
Sparfloxacin, an aminodifluoroquinolone, has in vitro activity against a wide range of gramnegative and gram-positive microorganisms. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. In vitro tests show that the combination of sparfloxacin and rifampin is antagonistic against Staphylococcus aureus. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J01MA09 | Sparfloxacin | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01M Quinolone antibacterials → J01MA Fluoroquinolones |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: NG | Registered Drug Product Database | Identifier(s): 04-7903 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
